Hohl Benjamin 4
4 · Enliven Therapeutics, Inc. · Filed Jul 14, 2025
Insider Transaction Report
Form 4
Hohl Benjamin
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
2025-07-10$22.66/sh−1,000$22,655→ 23,000 total - Exercise/Conversion
Common Stock
2025-07-10$2.48/sh+1,000$2,480→ 24,000 total - Exercise/Conversion
Stock Option (right to buy)
2025-07-10−1,000→ 114,806 totalExercise: $2.48Exp: 2031-08-02→ Common Stock (1,000 underlying)
Footnotes (3)
- [F1]The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $22.59 to $22.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]All of the shares subject to this option are fully vested and exercisable as of the date hereof.